Susquehanna International Group
TPTX

Susquehanna International Group’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Susquehanna International Group’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-134,600
Closed -$10.1M – 14793
2022
Q2 		$10.1M Buy
134,600
+125,800
+1,430% +$5.59M ﹤0.01% 2185
2022
Q1 		$236K Sell
8,800
-25,100
-74% -$843K ﹤0.01% 10847
2021
Q4 		$1.62M Buy
33,900
+22,900
+208% +$1.02M ﹤0.01% 6025
2021
Q3 		$731K Sell
11,000
-21,600
-66% -$1.54M ﹤0.01% 8388
2021
Q2 		$2.54M Buy
32,600
+8,300
+34% +$613K ﹤0.01% 5385
2021
Q1 		$2.3M Buy
24,300
+14,700
+153% +$1.75M ﹤0.01% 5589
2020
Q4 		$1.17M Sell
9,600
-7,700
-45% -$844K ﹤0.01% 6352
2020
Q3 		$1.51M Buy
+17,300
New +$1.21M ﹤0.01% 5166
2020
Q2 		– Sell
-36,500
Closed -$1.63M – 11252
2020
Q1 		$1.63M Buy
36,500
+32,800
+886% +$1.74M ﹤0.01% 4348
2019
Q4 		$230K Buy
+3,700
New +$176K ﹤0.01% 8516

Susquehanna International Group's TPTX Position: Q3 2022 in Review

Susquehanna International Group sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 31,218 shares — an estimated $2.35M sold.

Susquehanna International Group first reported a position in TPTX in Q4 2019 and held it in 11 quarters. The position peaked at $3.43M in Q4 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Susquehanna International Group reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Susquehanna International Group sold 31,218 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $2.35M.
  • Susquehanna International Group first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
  • Susquehanna International Group's Turning Point Therapeutics, Inc. Common Stock position peaked at $3.43M in Q4 2021.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Susquehanna International Group's 13F filing for Q3 2022, filed 14 Nov 2022.